Welcome to our lab (RauhLab), home of translational and transformative myeloid pathology and research!  Our focus is on genetic and immune pathogenesis of myeloid cancers, including myelodysplastic syndromes (MDS). More recently, we are expanding our focus to age-related, pre-leukemic, clonal hematopoiesis (called CH or ARCH or CHIP), and the impacts of monocytes, macrophages and neutrophils carrying CHIP mutations (especially in TET2 and DNMT3A) on related cardio-pulmonary, kidney and infectious diseases.

We strive to provide novel and more objective genomic and proteomic tests, in order to detect CHIP and myeloid cancer earlier.  By understanding how mutant clones manipulate and respond to the innate immune environment, we hope to discover novel biomarkers and treatment targets.  Applying this knowledge, our goal is to provide more personalized diagnosis and care and, ultimately, prevention of myeloid cancers and co-morbid diseases.​ 

Find out more about us, our Research and Accomplishments.

Our brand is “QMyPath” – “Q” for Queen’s, “My” for myeloid and the patient-focused nature of our research, and “Path” for pathology and the road to personalized medicine
RAW 264.7 macrophage-like cells - immunofluorescence
Translational molecular biology at work
NanoString nCounter
Beautiful Queen's University Campus on Lake Ontario
Dr. Rauh, Elina Cook, Christina Ferrone & Michael Luo, MDS Meeting, Vancouver 2019
Poster day
Lab lunch downtown, spring 2019
Lab lunch, University Club, Dec 2018
Nixon field, with Richardson Labs and KHSC in the background
Lots of fun activities on and off campus!